Omega-3 (triglyceride form).

The long polyunsaturated chains in omega-3 oxidize readily once exposed to air, and vitamin E is the fat-soluble antioxidant that sits in the same oil and slows that breakdown, which is why tocopherol is a standard addition to fish oil softgels. Taking in more of these fats also raises the body's vitamin E need, since additional tocopherol is spent keeping the fats intact.

Astaxanthin is a fat-soluble antioxidant that partitions into the same oil droplets as the omega-3 fats, where it helps limit peroxidation of their polyunsaturated chains. The two occur together naturally in krill oil, and blended formulations carry that same protective role.

Vitamin D3 is fat-soluble and is absorbed more completely when dietary fat is present in the gut, since it needs bile-formed micelles to cross into the bloodstream. The triglyceride form of omega-3 is itself a dietary fat, so taking the two together supplies that lipid carrier.

Coenzyme Q10 is a large, strongly fat-loving molecule that is taken up poorly on its own and far better alongside a lipid source, the reason it is usually delivered in oil. The omega-3 triglyceride oil can serve as that carrier when the two are taken together.

Triglyceride-form omega-3 has to be emulsified by bile salts before pancreatic lipase can release the fatty acids. Supplemental bile components are used to support that emulsification step where bile output is low.

The triglyceride form is a substrate, not a finished molecule: lipase cleaves EPA and DHA from the glycerol backbone at the oil-water interface. Blends that carry lipase act on that hydrolysis step.

Phospholipids lower the droplet size of an oil dose, which raises the surface area lipase can work on. This is long-standing formulation practice for fat-soluble actives.

Glutathione peroxidase is a selenium-dependent enzyme that clears lipid peroxides from membranes. As highly unsaturated fatty acids load into those membranes, demand on that selenoenzyme rises.

EPA shifts eicosanoid output toward less aggregatory thromboxane while ginkgolides act on platelet activating factor signalling. The two effects add on normal clotting, so stacking them is worth flagging rather than reading as a benefit.

Garlic organosulfur compounds damp platelet aggregation by a separate route from the thromboxane shift EPA produces. Combined, the effect on normal clotting is additive.

Vitamin K is the cofactor for carboxylating clotting factors, while long-chain omega-3 fatty acids push platelet behaviour the other way. The two sit on opposite sides of normal coagulation and read as counterweights, not a stacked benefit.

Omega-3 fatty acids lower hepatic triglyceride assembly and raise fatty acid oxidation, while nicotinic acid acts on adipose fatty acid release and VLDL output. The two support healthy blood lipid levels through separate mechanisms.

Clearing lipid peroxides consumes reduced glutathione, and cysteine availability sets the rate glutathione is resynthesised. A larger membrane load of unsaturated fatty acids raises that turnover.

Pancreatic lipase cleaves the sn-1 and sn-3 fatty acids from a triglyceride, leaving a 2-monoacylglycerol that the enterocyte absorbs. A triglyceride-form omega-3 is a direct substrate for that enzyme, which is exactly why it behaves like a dietary fat. Where pancreatic output is low, supplemental lipase addresses the rate-limiting step rather than the oil.

Phosphatidylcholine is an emulsifier that increases the lipid-water interface lipase can act on, and it also supplies the phospholipid shell chylomicrons need to leave the enterocyte. Both steps sit between a swallowed triglyceride and EPA or DHA in the blood. This is formulation and digestive biochemistry, not a claimed clinical effect.

Medium-chain triglycerides are hydrolysed quickly and stimulate bile and pancreatic secretion, which raises the digestive activity a long-chain omega-3 triglyceride depends on. They do not compete for the same incorporation sites because medium-chain fatty acids largely bypass chylomicron packaging. The pairing is about the vehicle and the meal context.

Linoleic acid and alpha-linolenic acid compete for the same delta-6 desaturase and elongase steps, and the downstream products push opposite eicosanoid balances. A high linoleic acid intake therefore shifts the ratio away from long-chain omega-3 derivatives. Preformed EPA and DHA in a triglyceride oil sidestep the desaturase bottleneck, which is the practical reason they are supplemented at all.

GLA is elongated to dihomo-gamma-linolenic acid, which competes with EPA and arachidonic acid for cyclooxygenase and lipoxygenase handling. Combining the two shifts which eicosanoid series predominates rather than simply adding effects. Formulations that pair them are deliberately setting a ratio.

Flaxseed oil supplies alpha-linolenic acid, which humans convert to EPA at a low and variable rate and to DHA at a lower one still. It is a precursor source, not an equivalent to a preformed EPA and DHA triglyceride. Supplying both means the pathway is loaded at two points.

EPA is one of the two fatty acids a marine triglyceride oil is standardised for, and adding isolated EPA changes the EPA to DHA ratio of the total intake. The two compete for the same phospholipid incorporation positions, so a higher EPA share reduces membrane DHA enrichment. Ratio, not total dose, is what changes here.

DHA occupies the sn-2 position of neural and retinal phospholipids and is the fatty acid a brain- or eye-oriented formula is weighted toward. Added isolated DHA raises its share against EPA within the same triglyceride matrix. The change is compositional.

Long-chain polyunsaturated fatty acids carry many double bonds and oxidise readily, both in the bottle and in membranes once incorporated. Tocotrienols distribute into lipid phases and interrupt peroxidation chain propagation. This protects the oil's integrity, a chemical endpoint rather than a health one.

Rosemary extract, standardised for carnosic acid and rosmarinic acid, is a routine oxidation inhibitor in marine and seed oils. It sits in the formula to keep peroxide and anisidine values low across shelf life. Its role is stability, not a physiological one.

Free ferrous iron generates hydroxyl radicals from peroxides and is a classic initiator of polyunsaturated fatty acid peroxidation. Taking a high-dose iron salt in the same swallow as a polyunsaturated oil puts an oxidant next to a highly oxidisable substrate. Separating them and supplying a lipid antioxidant is ordinary practice.

Divalent calcium binds free fatty acids released by lipase to form insoluble soaps that pass unabsorbed. Large calcium doses taken with a fat load reduce the fraction of that fat absorbed. The interaction is with the liberated fatty acids, so it applies to any triglyceride oil taken alongside.

EPA-derived eicosanoids reduce platelet aggregation, and nattokinase acts on fibrin. The two push the same direction on haemostasis by different mechanisms, so the combined effect on bleeding tendency deserves counting. Anyone on an anticoagulant or facing a procedure should raise the combination with their clinician.

Willow bark salicin is metabolised to salicylic acid, which inhibits platelet cyclooxygenase. Marine omega-3 fatty acids shift thromboxane production in the same direction. The additive effect on platelet function is the point to flag.

Long-chain fatty acids cannot enter mitochondria without carnitine-mediated shuttling through CPT1 and CPT2. Carnitine availability therefore sits directly downstream of any long-chain fatty acid load. This is transport biochemistry and says nothing on its own about a clinical outcome.

Curcumin and EPA-derived mediators both act on the arachidonic acid cascade, curcumin partly by inhibiting cyclooxygenase and lipoxygenase steps. Curcumin is also poorly water-soluble and absorbs better with a fat load, which a triglyceride oil supplies. Two separate reasons the pair is co-formulated.

Plant sterols crowd cholesterol and other lipids out of intestinal mixed micelles, which is the mechanism behind their effect on cholesterol absorption. That same micellar space carries the products of triglyceride hydrolysis. Whether this changes EPA and DHA uptake meaningfully at supplement doses is not established, so the pairing is flagged rather than asserted.

Psyllium forms a viscous gel that slows diffusion of bile salts and lipolysis products to the mucosal surface. A soluble fibre dose in the same swallow as an oil is the situation where that matters. Spacing the two is a practical formulation answer.

Krill oil delivers EPA and DHA bound to phospholipids rather than a glycerol triglyceride backbone, so the same fatty acids arrive on a different carrier. Stacking both raises total EPA and DHA and mixes two carrier chemistries. Neither carrier is presented here as preferable. They differ in how the fatty acids are esterified.

Glutathione peroxidase 4 reduces lipid hydroperoxides inside membranes using glutathione as the electron donor, and membranes enriched in EPA and DHA generate more of those hydroperoxides. Glutathione status is therefore part of handling a polyunsaturated fat load. Selenium is the required cofactor for that enzyme.